Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy

Neurology

Volumn 74, Issue 8, 2010, Pages 651-657

  Hughes, R A C ^a   Gorson, K C ^b   Cros, D ^c   Griffin, J ^d   Pollard, J ^e   Vallat, J M ^f   Maurer, S L ^g   Riester, K ^h   Davar, G ^h   Dawson, K ^h   Sandrock, A ^h  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Service de Neurologie   (France)

^g Scientific Connexions   (United States)

^h BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; IMMUNOGLOBULIN G4; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; MALE; MULTICENTER STUDY; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 77649097161     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d1a862     Document Type: Article

References (26)

1. Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-1356.
2. Hughes RA, Allen D, Makowska A, Gregson NA. Patho-genesis of chronic inflammatory demyelinating polyra-diculoneuropathy. J Peripher Nerv Syst 2006;11:30-46. (Pubitemid 43344973)
3. Yan WX, Archelos JJ, Hartung HP, et al. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:286-292.
4. Chiò A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemi-ological study in Italy. J Neurol Neurosurg Psychiatry 2007;78:1349-1353.
5. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyra-diculoneuropathy: a double-blind, sham-controlled, crossover study. Brain 1996;119:1055-1066.
6. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neu-rol 1994;36:838-845.
7. Dyck PJ, Obrien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculo-neuropathy more than no treatment. Ann Neurol 1982; 11:136-141.
8. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56:445-449.
9. van Schaik I, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demy-elinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002;CD001797.
10. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004;CD003280.
11. RMC Trial Group. Randomised controlled trial of metho-trexate for chronic inflammatory demyelinating polyra-diculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009;8:158-164.
12. Choudhary PP, Hughes RAC. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM 1995;88:493-502.
13. Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al. Interferon-/31a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999;53:1364-1365.
14. Martina ISJ, van Doorn PA, Schmitz PIM, Meulstee J, van der Meche FGA. Chronic motor neuropathies: response to interferon-/3-1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry 1999;66:197-201.
15. Vallat JM, Hahn AF, Leger JM, et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003; 60(suppl 3):S23-S28.
16. Hadden RDM, Sharrack B, Bensa S, Soudain SE, Hughes RAC. Randomized trial of interferon /3-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999;53:57-61.
17. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2003;74:99-104.
18. Rudick RA, Miller D, Hass S, et al, for the AFFIRM and SENTINEL Investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007;62:307-308.
19. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I: conceptual framework and item selection. Med Care 1992;30:473-483.
20. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-343.
21. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1ain multiple sclerosis: Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998;50:1266-1272.
22. Villa AM, Garcea O, Di Egidio M, Saizar R, Sica REP. Interferon /3-1a in chronic inflammatory demyelinating polyneuropathy [case report]. Arq Neuropsiquiatr 2004; 62:892-894.
23. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-144.
24. Clanet M, Kappos L, Hartung H-P, Hohlfeld R, the European IFN/3-1a Dose-Comparison Study Investigators. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler 2004;10:139-144.
25. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon /3-1a in relapsing MS. Neurology 2002;59:1507-1517.
26. Jacobs LD, Cookfair DL, Rudick RA, et al, and the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.